Genpharmasec Ltd (531592)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Genpharmasec's revenue was ₹49.7 Cr (+312.9% year on year, -10.3% on the previous quarter), and net profit ₹-0.2 Cr (against a profit a year earlier); the operating margin was 1.9%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹49.7 | +312.9% | -10.3% |
| Operating profit | ₹1.0 | +1.9% | -51.9% |
| Net profit | ₹-0.2 | to loss | to loss |
| EPS (₹) | 0.00 | -100.0% | -100.0% |
| Operating margin | 1.9% | — | — |
📢 Recent Corporate Announcements
Promoter Rajesh Mirchumal Sadhwani acquired 50,00,000 equity shares (0.90% of total voting capital) of Genpharmasec Ltd through open market purchase on August 28, 2026. Following this transaction, his personal holding increased from 13.18% (7,30,00,000 shares) to 14.09% (7,80,00,000 shares). Total promoter group holding (including PAC Sneha Sadhwani) increased from 29.98% (16,60,01,000 shares) to 30.88% (17,10,01,000 shares). The total paid-up equity share capital remains unchanged at Rs 55.37 Cr divided into 55,37,19,700 equity shares of Re. 1 each.
- 50,00,000 shares (0.90% stake) acquired by promoter Rajesh Sadhwani via open market on August 28, 2026
- Acquirer's direct holding increased from 13.18% (7.30 Cr shares) to 14.09% (7.80 Cr shares)
- Combined promoter and PAC holding crossed 30%, rising from 29.98% to 30.88% (17.10 Cr shares)
- Total equity share capital stands at Rs 55,37,19,700 across 55,37,19,700 equity shares of Re. 1 each
Genpharmasec Ltd has scheduled a Board of Directors meeting on September 2, 2026, to finalize administrative matters concerning its 34th Annual General Meeting (AGM) for the fiscal year ended March 31, 2026. Key agenda items include approving the draft notice, setting the AGM date and mode, fixing the e-voting cut-off dates, and approving the FY26 Directors' Report and Annual Report. The board will also approve the closure of share transfer books and appoint a scrutinizer for e-voting. This is a standard compliance procedure with no immediate impact on business operations or financials.
- Board meeting scheduled for September 02, 2026
- Agenda to approve Notice and Calendar of Events for the 34th Annual General Meeting
- Board to review and approve the Directors' Report and Annual Report for FY2025-26
- To fix cut-off date and timeline for member e-voting rights
Genpharmasec Ltd has entered into a non-exclusive Super Stockist agreement with Amneal Healthcare Private Limited (AHPL), a subsidiary of the US-based Amneal Pharmaceuticals. Under the terms, AHPL has provided a minimum annual sales commitment of approximately ₹75 Crores for each calendar year. This is a highly material development for Genpharmasec, as the commitment value exceeds its current net worth of ₹71 Crores. The company will distribute AHPL's products to wholesale and retail pharmacists across specified territories.
- Minimum annual sales commitment of approximately ₹75 Crores per calendar year.
- The commitment value of ₹75 Cr represents approximately 105.6% of the company's current net worth of ₹71 Cr.
- Partner AHPL is part of Amneal Pharmaceuticals, which has invested over $300 million in India over the last 15 years.
- Genpharmasec will act as a non-exclusive Super Stockist for products manufactured by AHPL and its third-party licensors.
- The agreement marks a significant scale-up from the company's existing diagnostic equipment distribution business.
Genpharmasec Ltd has confirmed zero deviation in the utilization of ₹4,845.05 Lakhs raised through its Rights Issue allotted on February 21, 2024. As of June 30, 2026, the company has fully utilized funds for the acquisition of Derren Healthcare (₹14.43 Cr), working capital (₹16.50 Cr), and general corporate purposes (₹11.38 Cr). A portion of the debt repayment allocation remains, with ₹2.89 Cr spent against an original allocation of ₹5.88 Cr. The Audit Committee has reviewed and confirmed that all funds are being deployed as per the original Letter of Offer.
- Total funds raised via Rights Issue on February 21, 2024, amounted to ₹4,845.05 Lakhs.
- ₹1,443.58 Lakhs fully utilized to acquire equity shares of Derren Healthcare Private Limited.
- ₹1,650.00 Lakhs fully deployed towards meeting working capital requirements.
- ₹289.00 Lakhs utilized for debt repayment out of the allocated ₹588.00 Lakhs as of June 30, 2026.
- Zero deviation or variation reported across all five primary objects of the issue.
Genpharmasec reported a sharp decline in consolidated net profit to ₹0.23 Cr for Q1 FY27, down from ₹1.22 Cr in the same quarter last year. While consolidated revenue grew 313% YoY to ₹49.71 Cr, it declined 10% sequentially from the March 2026 quarter. The bottom line was severely pressured by losses in the Manufacturing & Processing segment (₹1.25 Cr loss) and Laboratory Testing (₹0.29 Cr loss), which offset the ₹2.22 Cr profit from the core Pharmaceutical trading business.
- Consolidated Revenue increased 313% YoY to ₹49.71 Cr from ₹12.04 Cr in June 2025.
- Consolidated Net Profit fell 81% YoY to ₹0.23 Cr compared to ₹1.22 Cr in the previous year's quarter.
- Manufacturing & Processing segment reported a significant loss of ₹1.25 Cr on revenue of ₹2.72 Cr.
- Pharmaceutical segment remains the sole profit driver with a segment result of ₹2.22 Cr.
- Total Comprehensive Income for the group turned into a marginal loss of ₹0.58 Lakhs after accounting for non-controlling interests.
Genpharmasec reported a sharp increase in consolidated revenue to ₹49.71 Cr for Q1 FY27, up from ₹12.04 Cr in Q1 FY26, driven primarily by the Pharmaceutical segment. However, consolidated net profit fell to ₹0.23 Cr from ₹1.22 Cr in the year-ago period, largely due to losses in the Manufacturing & Processing division. The core Pharmaceutical segment remains the primary profit driver with a segment PBT of ₹2.22 Cr. Standalone performance was relatively stable with a PAT of ₹1.57 Cr, but consolidated results were weighed down by non-core segment underperformance.
- Consolidated Revenue from operations grew 313% YoY to ₹49.71 Cr in Q1 FY27.
- Pharmaceutical segment contributed ₹44.78 Cr to revenue, representing 90% of total consolidated turnover.
- Manufacturing & Processing segment reported a loss of ₹1.25 Cr at the PBT level, acting as a major drag on consolidated earnings.
- Consolidated Net Profit attributable to the parent company stood at ₹0.26 Cr, a significant decline from ₹1.22 Cr in Q1 FY26.
- Standalone PAT remained flat at ₹1.57 Cr compared to ₹1.56 Cr in the previous year's quarter.
Genpharmasec Ltd has scheduled a board meeting for August 11, 2026, to approve its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company is coming off a high-growth year where FY26 revenue reached Rs 131 Cr, a significant jump from Rs 33 Cr in FY25. However, operating margins remain thin at 1.9%, and the stock is currently trading at a low price of Rs 1.0 with a market cap of Rs 63 Cr. The trading window for insiders has been closed since July 01, 2026.
- Board meeting scheduled for August 11, 2026, to approve Q1 FY27 results
- Trading window closed from July 01, 2026, until 48 hours post-announcement
- Company reported a significant revenue increase to Rs 131.0 Cr in FY26
- Operating profit margin (TTM) stands at a narrow 1.9%
- Promoter holding remains stable at 29.98% as of June 2026
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
